PL2024375T3 - Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV - Google Patents

Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV

Info

Publication number: PL2024375T3
Authority: PL; Poland
Prior art keywords: hcv ns5b; ns5b inhibitors; cyclopropyl fused; fused indolobenzazepine; indolobenzazepine hcv
Prior art date: 2006-05-17

Application number

PL07761873T

Other languages

English (en)

Inventor

John A Bender

Min Ding

Robert G Gentles

Piyasena Hewawasam

Original Assignee

Bristol Myers Squibb Holdings Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-17

Filing date

2007-05-04

Publication date

2011-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2024375(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-04 Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland

2011-07-29 Publication of PL2024375T3 publication Critical patent/PL2024375T3/pl

Links

JYGUARFTLQSWDG-UHFFFAOYSA-N 3,12-diazatetracyclo[9.7.0.02,8.013,18]octadeca-1,3,5,7,9,11,13,15,17-nonaene Chemical compound C1=CC=NC2=C3C4=CC=CC=C4N=C3C=CC2=C1 JYGUARFTLQSWDG-UHFFFAOYSA-N 0.000 title 1
101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

PL07761873T 2006-05-17 2007-05-04 Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV PL2024375T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US80112506P	2006-05-17	2006-05-17
US80200506P	2006-05-19	2006-05-19
US85208406P	2006-10-16	2006-10-16
US89475707P	2007-03-14	2007-03-14
EP07761873A EP2024375B1 (en)	2006-05-17	2007-05-04	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
PCT/US2007/068209 WO2007136982A1 (en)	2006-05-17	2007-05-04	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number	Publication Date
PL2024375T3 true PL2024375T3 (pl)	2011-07-29

Family

ID=38512732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07761873T PL2024375T3 (pl)	2006-05-17	2007-05-04	Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV

Country Status (24)

Country	Link
US (1)	US7456166B2 (pl)
EP (1)	EP2024375B1 (pl)
JP (1)	JP5284952B2 (pl)
KR (1)	KR101417145B1 (pl)
AR (1)	AR061008A1 (pl)
AT (1)	ATE501156T1 (pl)
AU (1)	AU2007253998B2 (pl)
BR (1)	BRPI0711821A2 (pl)
CA (1)	CA2651690C (pl)
CY (1)	CY1111526T1 (pl)
DE (1)	DE602007013036D1 (pl)
DK (1)	DK2024375T3 (pl)
EA (1)	EA015286B1 (pl)
HR (1)	HRP20110194T1 (pl)
IL (1)	IL195025A (pl)
MX (1)	MX2008014435A (pl)
NO (1)	NO341663B1 (pl)
NZ (1)	NZ572555A (pl)
PE (1)	PE20080070A1 (pl)
PL (1)	PL2024375T3 (pl)
SI (1)	SI2024375T1 (pl)
TW (1)	TWI401244B (pl)
WO (1)	WO2007136982A1 (pl)
ZA (1)	ZA200809548B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1688420A4 (en) *	2003-11-19	2008-10-22	Japan Tobacco Inc	5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en)	2004-11-12	2010-02-09	Japan Tobacco Inc.	Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) *	2006-05-17	2009-04-21	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) *	2006-05-25	2010-08-12	Bristol-Myers Squibb Company	Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7541351B2 (en) *	2007-01-11	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7541352B2 (en) *	2007-02-02	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7517872B2 (en) *	2007-02-22	2009-04-14	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7998951B2 (en) *	2007-03-05	2011-08-16	Bristol-Myers Squibb Company	HCV NS5B inhibitors
EP2121694B1 (en)	2007-03-13	2014-07-16	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7521444B2 (en) *	2007-03-14	2009-04-21	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7541353B2 (en) *	2007-03-14	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7547690B2 (en) *	2007-03-14	2009-06-16	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US7538102B2 (en) *	2007-03-14	2009-05-26	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US7538103B2 (en) *	2007-03-15	2009-05-26	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
ES2381410T3 (es)	2007-05-04	2012-05-28	Vertex Pharmceuticals Incorporated	Terapia de combinación paa el tratamiento de infecciones por VHC
US7652004B2 (en) *	2007-08-09	2010-01-26	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7642251B2 (en) *	2007-08-09	2010-01-05	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US8143243B2 (en) *	2007-08-09	2012-03-27	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
AU2007361468A1 (en) *	2007-11-20	2009-05-28	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8129367B2 (en) *	2007-11-21	2012-03-06	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US8124601B2 (en) *	2007-11-21	2012-02-28	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
WO2009076747A1 (en)	2007-12-19	2009-06-25	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US8524716B2 (en) *	2007-12-24	2013-09-03	Janssen R&D Ireland	Macrocyclic indoles as hepatitis C virus inhibitors
US8138171B2 (en) *	2008-03-27	2012-03-20	Bristol-Myers Squibb Company	Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
MX2010010061A (es) *	2008-03-27	2010-09-30	Bristol Myers Squibb Co	Compuestos para el tratamiento de hepatitis c.
JP2011515484A (ja) *	2008-03-27	2011-05-19	ブリストル−マイヤーズスクイブカンパニー	ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8133884B2 (en) *	2008-05-06	2012-03-13	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
TWI454476B (zh) *	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010080874A1 (en)	2009-01-07	2010-07-15	Scynexis, Inc.	Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8143244B2 (en) *	2009-02-26	2012-03-27	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2011161232A1 (en)	2010-06-24	2011-12-29	Tibotec Pharmaceuticals	PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
US20120196794A1 (en)	2010-08-06	2012-08-02	Bristol-Myers Squibb Company	Combinations of Hepatitis C Virus Inhibitors
CN106986862A (zh)	2010-12-22	2017-07-28	Abbvie 公司	丙型肝炎抑制剂及其用途
WO2012092411A2 (en)	2010-12-30	2012-07-05	Enanta Pharmaceuticals, Inc.	Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8716275B2 (en) *	2011-10-20	2014-05-06	Bristol-Myers Squibb Company	Compound for the treatment of hepatitis C
CA2879398A1 (en) *	2012-07-18	2014-01-23	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US752354A (en) *		1904-02-16		Composition post
US753137A (en) *		1904-02-23		Dust-pan
US756203A (en) *	1903-11-14	1904-04-05	Oliver E Barthel	Muffler.
PT1719773E (pt)	2004-02-24	2009-06-03	Japan Tobacco Inc	Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en)	2004-08-09	2008-03-25	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
EP1799679B1 (de)	2004-10-13	2008-01-23	Merck Patent GmbH	Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
CA2585084A1 (en)	2004-10-26	2006-05-04	Immacolata Conte	Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en)	2005-09-09	2005-10-19	Angeletti P Ist Richerche Bio	Therapeutic compounds
US7399758B2 (en)	2005-09-12	2008-07-15	Meanwell Nicholas A	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en)	2005-09-13	2009-01-06	Bristol-Myers Squibb Company	Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en)	2006-02-08	2008-11-25	Bristol-Myers Squibb Company	HCV NS5B inhibitors
GB0608928D0 (en) *	2006-05-08	2006-06-14	Angeletti P Ist Richerche Bio	Therapeutic agents

2007
- 2007-05-03 US US11/743,921 patent/US7456166B2/en not_active Expired - Fee Related
- 2007-05-04 SI SI200730612T patent/SI2024375T1/sl unknown
- 2007-05-04 DK DK07761873.4T patent/DK2024375T3/da active
- 2007-05-04 MX MX2008014435A patent/MX2008014435A/es active IP Right Grant
- 2007-05-04 JP JP2009511151A patent/JP5284952B2/ja active Active
- 2007-05-04 AT AT07761873T patent/ATE501156T1/de active
- 2007-05-04 HR HR20110194T patent/HRP20110194T1/hr unknown
- 2007-05-04 PL PL07761873T patent/PL2024375T3/pl unknown
- 2007-05-04 KR KR1020087027866A patent/KR101417145B1/ko not_active Expired - Fee Related
- 2007-05-04 NZ NZ572555A patent/NZ572555A/en unknown
- 2007-05-04 WO PCT/US2007/068209 patent/WO2007136982A1/en not_active Ceased
- 2007-05-04 CA CA2651690A patent/CA2651690C/en not_active Expired - Fee Related
- 2007-05-04 DE DE602007013036T patent/DE602007013036D1/de active Active
- 2007-05-04 AU AU2007253998A patent/AU2007253998B2/en not_active Ceased
- 2007-05-04 EP EP07761873A patent/EP2024375B1/en not_active Not-in-force
- 2007-05-04 EA EA200802346A patent/EA015286B1/ru not_active IP Right Cessation
- 2007-05-04 BR BRPI0711821-0A patent/BRPI0711821A2/pt not_active IP Right Cessation
- 2007-05-15 PE PE2007000585A patent/PE20080070A1/es active IP Right Grant
- 2007-05-17 TW TW096117512A patent/TWI401244B/zh not_active IP Right Cessation
- 2007-05-17 AR ARP070102138A patent/AR061008A1/es active IP Right Grant
2008
- 2008-10-30 IL IL195025A patent/IL195025A/en not_active IP Right Cessation
- 2008-11-04 NO NO20084637A patent/NO341663B1/no not_active IP Right Cessation
- 2008-11-07 ZA ZA2008/09548A patent/ZA200809548B/en unknown
2011
- 2011-06-03 CY CY20111100539T patent/CY1111526T1/el unknown

Also Published As

Publication number	Publication date
CY1111526T1 (el)	2016-02-10
EP2024375A1 (en)	2009-02-18
HK1122814A1 (en)	2009-05-29
HRP20110194T1 (hr)	2011-04-30
BRPI0711821A2 (pt)	2012-01-17
KR20090008344A (ko)	2009-01-21
CA2651690A1 (en)	2007-11-29
NO20084637L (no)	2008-12-15
JP2009537557A (ja)	2009-10-29
NO341663B1 (no)	2017-12-18
KR101417145B1 (ko)	2014-07-08
IL195025A0 (en)	2009-08-03
DK2024375T3 (da)	2011-06-27
EP2024375B1 (en)	2011-03-09
AU2007253998A1 (en)	2007-11-29
NZ572555A (en)	2010-11-26
US20070270405A1 (en)	2007-11-22
IL195025A (en)	2013-09-30
ATE501156T1 (de)	2011-03-15
EA200802346A1 (ru)	2009-06-30
EA015286B1 (ru)	2011-06-30
DE602007013036D1 (de)	2011-04-21
TW200804282A (en)	2008-01-16
MX2008014435A (es)	2008-11-27
ZA200809548B (en)	2009-12-30
CA2651690C (en)	2014-11-04
SI2024375T1 (sl)	2011-10-28
PE20080070A1 (es)	2008-03-10
US7456166B2 (en)	2008-11-25
WO2007136982A1 (en)	2007-11-29
AU2007253998B2 (en)	2012-03-15
TWI401244B (zh)	2013-07-11
AR061008A1 (es)	2008-07-30
JP5284952B2 (ja)	2013-09-11

Publication	Publication Date	Title
ZA200809548B (en)	2009-12-30	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
IL198401A0 (en)	2010-02-17	Hcv ns3 protease inhibitors
IL197907A0 (en)	2009-12-24	Hcv nucleoside inhibitor
HRP20160410T8 (hr)	2019-04-19	Inhibitori hepatitis c virusa
IL233818A0 (en)	2014-09-30	Inhibitors to ns5a hcv
IL213278A0 (en)	2011-07-31	Inhibitors of hcv ns5a
ZA201008988B (en)	2012-01-25	Hcv protease inhibitors
IL195515A0 (en)	2011-08-01	Macrocyclic oximyl hepatitis c protease inhibitors
EP2410841A4 (en)	2012-10-24	SUBSTITUTED BICYCLIC HCV INHIBITORS
SI2094702T1 (sl)	2016-03-31	Virusni inhibitorji
IL189626A0 (en)	2008-08-07	Benzodiazepines as hcv inhibitors
EP2432318A4 (en)	2012-11-21	NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
GB2439606B (en)	2011-08-17	An oscillator
ZA200902475B (en)	2010-03-31	HCV NS3 Protease Inhibitors
ZA200711069B (en)	2009-03-25	HCV inhibitors
ZA200903379B (en)	2010-07-28	Hepatitis C virus inhibitors
GB0611451D0 (en)	2006-07-19	Cellular antagonist
HUS1500008I1 (hu)	2016-10-28	Hepatitis C vírus inhibitorok
AU313339S (en)	2007-03-20	Chiller bottle
AU313340S (en)	2007-03-20	Chiller bottle
ZA200903014B (en)	2010-07-28	Hepatitis C virus inhibitors
ZA200810235B (en)	2009-10-28	Macrocyclic oximyl hepatitis C protease inhibitors